Giannini C - Search Results

1

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.

Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Allen C, et al. Among authors: giannini c. Cancer Res. 2006 Dec 15;66(24):11840-50. doi: 10.1158/0008-5472.CAN-06-1200. Cancer Res. 2006. PMID: 17178881

2

Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma.

Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD. Giannini C, et al. Neurogenetics. 2001 Jul;3(3):159-62. doi: 10.1007/s100480100116. Neurogenetics. 2001. PMID: 11523567

3

Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.

Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Phuong LK, et al. Among authors: giannini c. Cancer Res. 2003 May 15;63(10):2462-9. Cancer Res. 2003. PMID: 12750267

4

Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.

Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Aldape KD, et al. Among authors: giannini c. J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7. doi: 10.1093/jnen/63.7.700. J Neuropathol Exp Neurol. 2004. PMID: 15290895

5

Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.

Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Allen C, et al. Among authors: giannini c. J Gene Med. 2004 Nov;6(11):1216-27. doi: 10.1002/jgm.616. J Gene Med. 2004. PMID: 15459967

6

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Giannini C, et al. Neuro Oncol. 2005 Apr;7(2):164-76. doi: 10.1215/S1152851704000821. Neuro Oncol. 2005. PMID: 15831234 Free PMC article.

7

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD. Sarkaria JN, et al. Among authors: giannini c. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71. doi: 10.1158/1078-0432.CCR-05-2510. Clin Cancer Res. 2006. PMID: 16609043

8

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

Krishnan S, Brown PD, Ballman KV, Fiveash JB, Uhm JH, Giannini C, Jaeckle KA, Geoffroy FJ, Nabors LB, Buckner JC; North Central Cancer Treatment Group. Krishnan S, et al. Among authors: giannini c. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9. doi: 10.1016/j.ijrobp.2006.01.018. Epub 2006 Apr 19. Int J Radiat Oncol Biol Phys. 2006. PMID: 16626884 Clinical Trial.

9

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC. Jenkins RB, et al. Among authors: giannini c. Cancer Res. 2006 Oct 15;66(20):9852-61. doi: 10.1158/0008-5472.CAN-06-1796. Cancer Res. 2006. PMID: 17047046

10

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.

Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Sarkaria JN, et al. Among authors: giannini c. Mol Cancer Ther. 2007 Mar;6(3):1167-74. doi: 10.1158/1535-7163.MCT-06-0691. Mol Cancer Ther. 2007. PMID: 17363510

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,028 results

Search Page

Filters